This biennial, multidisciplinary, one-day conference will provide an update on the clinical management of patients with kidney and bladder (urothelial) cancers. Didactic lectures will present the many recent advances in the treatment of these diseases and their integration into the multidisciplinary management of patients with early stage, high risk, and metastatic disease. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them.. Interactive discussions with experts in the field will enhance the learning experience.

Objectives

Discuss current status of adjuvant therapy for patients with high risk kidney cancer.

Analyze treatment options for second line therapy for immune therapy resistant kidney cancer.

Evaluate the role of immune therapy alone and in combination for patients with kidney cancer.

Discuss the current approaches to treatment of patients with non clear cell kidney cancer.

Evaluate the changing role of VEGF therapy in patients with kidney cancer.

Analyze current unresolved clinical management issues and clinical research opportunities.

Evaluate the role of surgery in the management of patients with all stages of kidney cancer

Analyze critical clinical questions in urothelial carcinoma that are being addressed by clinical research.

Recognize drug therapies used in the treatment of clear cell RCC and non clear cell RCC.

Explain the role of cytoreductive nephrectomy in the treatment of RCC.

Recognize toxicities and optimize the management of class-specific side effects of renal cell carcinoma therapies including immunotherapy and VEGFR TKIs.

Utilize multidisciplinary evaluation and assessment to contribute to more effective and expedited patient treatment.

Recognize toxicities and optimize the management of class-specific side effects of bladder cancer therapies.

Analyze the current available treatment approaches including systemic and novel treatments, in non-muscle invasive bladder cancer.

Discuss the role of immunotherapy in the treatment of bladder and kidney cancers.

Identify common immune related adverse effects and their management based on current guidelines and evidence.

Registration

Registration Fees:

Physician $150

Resident/Fellow $50

Physician Assistant $50

Nurse Practitioner $50

Nurse $50

Allied Health Professional $50

Pharmacists $50

Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 7.25 Interprofessional Continuing Education (IPCE) credits for learning and change.